Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024
First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-of-care screening test1
“Cancer is the second-leading cause of death in the
The abstracts featured at AACR 2024 are as follows:
Title: Performance of a multi-analyte, multi-cancer early detection (MCED) blood test in a prospectively collected cohort
Presenter: Diehl, F
Session:
Poster number: LB100/11
Location: Section 51
Key findings: First analysis of the refined multi-biomarker class MCED test achieved an overall sensitivity of 50.9% with 98.5% specificity and 56.8% sensitivity when breast and prostate cancer were excluded from the analysis. Sensitivity was 54.8% for cancers without standard-of-care screening for average-risk populations and 63.7% in the most aggressive cancers with the shortest 5-year survival rate (pancreas, esophagus, liver, lung and bronchus, stomach, and ovary).
Title: Case report: DETECT-A participants with pre-malignant conditions
Presenter: Rego, SP
Session:
Poster number: 2449/14
Location: Section 41
Key findings: Results showed that in the rare instance when MCED testing detected pre-cancerous conditions in the DETECT-A study, surgical interventions prevented cancer development, and all patients were cancer-free at follow-up.
About the ASCEND-2 study
The ASCEND-2 (Ascertaining Serial Cancer patients to Enable New Diagnostic 2) study is a large, multi-center, prospective, case-control study of clinically characterized participants. Key goals of the study are to develop the algorithm and identify the biomarkers to inform the final design of the Cancerguard™ test, Exact Sciences’ investigational, multi-biomarker class blood-based MCED test. ASCEND-2 has enrolled over 11,000 participants across 151 sites within the
About the DETECT-A study
The DETECT-A (Detecting cancers Early Through Elective mutation-based blood Collection and Testing) study was the first-ever large, prospective, interventional study to use a blood test to detect multiple types of cancer in a real-world setting. The DETECT-A study enrolled more than 10,000 women with no history of cancer to determine if a blood test in combination with standard-of-care screenings could detect cancers before signs and symptoms appeared. The CancerSEEK test, the MCED test studied in DETECT-A, was the forerunner to the Cancerguard test, the MCED test currently in development at
About the Cancerguard™ test
The Cancerguard test, currently in development, is designed to detect multiple cancers in their earliest stages from a single blood draw. Building upon decades of research,
About
A leading provider of cancer screening and diagnostic tests,
Forward-looking statements
This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the development and commercialization of the Cancerguard test; the performance characteristics and healthcare benefits of the Cancerguard test; and the timing and anticipated results of FDA or any other national regulatory authority submission. Risks and uncertainties that may affect our forward-looking statements are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the
References
- Gainhullin V., et. al. Abstract #LB100/11, AACR 2024.
-
American Cancer Society . Cancer facts and figures 2024. AccessedApril 3, 2024 . https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf -
Hawkes,
N. Cancer survival data emphasise importance of early diagnosis. BMJ. 2019; doi:10.1136/bmj.l408 -
Siegel RL, Giaquinto AN,
Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; doi:10.3322/caac.21820 - Choudhry, O., et. al. Abstract #2449/14, AACR 2024.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408436394/en/
Media (
+1 608-345-8010
msmulevitz@exactsciences.com
Media (Outside the US):
Federico Maiardi
+41 79-138-1326
fmaiardi@exactsciences.com
Investors:
+1 608 535-8659
investorrelations@exactsciences.com
Source: